XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
ASSET ACQUISITION (Details Narrative) - USD ($)
Nov. 09, 2021
Nov. 30, 2021
Aug. 31, 2021
Amount received $ 15,000,000    
Intangible assets $ 178,000    
Useful life asset 21 years    
Amortization $ 8,476    
Cash consideration paid $ 39,500,000    
Interest on royalty,percentage 8.00%    
Common stock value per share   $ 0.001 $ 0.001
Common stock value   $ 20,020 $ 188
Common stock shares issued 555,556 20,020,239 188,616
Debt discount $ 55,556    
Mioxal [Member]      
Useful life asset 24 years    
Amortization $ 3,385,409    
S T Bio Sciences Ltd      
Cash consideration paid $ 350,000    
Common stock value per share $ 2.05    
Common stock value $ 40,654,827    
Common Stock fully diluted aggregate fair value $ 41,004,827    
Common stock shares issued 19,831,623    
Debt discount $ 500,000    
Shares acquired 19,831,623    
S T Bio Sciences Ltd | Tranche One [Member]      
Amount received $ 4,000,000    
S T Bio Sciences Ltd | Tranche Two [Member]      
Amount received 5,000,000    
S T Bio Sciences Ltd | September 10, 2024 [Member] | Tranche Three [Member]      
Amount received 6,000,000    
Ingenius Biotech [Member]      
Current and long-term liabilities 39,500,000    
Ingenius Biotech [Member] | January 15, 2022 [Member]      
Asset acquisition first installment 1,500,000    
Asset acquisition thereafter 3,500,000    
Asset acquisition aggregate amount 24,500,000    
Additional liabilities assumed 423,000    
Ingenius Biotech [Member] | April 15, 2022 [Member]      
Asset acquisition second installment $ 1,500,000